Compare KB Financial Group, Inc. (KB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KB Financial Group, Inc. vs Novo Nordisk A/S — how do they compare? KB Financial Group, Inc. trades at $121.96 (market cap $44.15B), while Novo Nordisk A/S trades at $38.11 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 3.8× KB Financial Group, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold KB Financial Group, Inc. for 33 Days and Novo Nordisk A/S for 116 Days on average.
| KB | NVO | |
|---|---|---|
Market Cap | $44.15B | $168.73B |
Volume | 131,395 | 13,531,267 |
Sector | Financials | Health |
52-Week High | $132.88 | $63.98 |
52-Week Low | $77.50 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $215.53T | $183.05B |
Dividend Yield | 2.65% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KB Financial Group trades at $124.73, showing minimal daily movement with a slight decline of 0.02%. The stock exhibits neutral technical signals while maintaining strong fundamental performance with consistent earnings beats and improving profitability. Recent quarterly results exceeded expectations, with Q2 2026 EPS of $3.79 beating estimates of $3.51. The company demonstrates solid revenue growth, climbing from $17.77T in 2022 to $21.23T in 2025, with net income margins expanding to 27.47%.
KB presents an attractive value proposition with a P/E of 9.92 and P/B of 0.97, trading below book value. Analyst sentiment is mixed with 33% buy ratings but strong institutional interest. Key risks include banking sector volatility and interest rate sensitivity, while opportunities lie in South Korea's outperforming market and the company's expanding non-banking activities driving fee income growth.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
